Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05759962 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of LQT-1213 in Healthy Adults
A Phase 1 study, sponsored by Thryv Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT05759962 is a Phase 1 study that has completed, run by Thryv Therapeutics. The registered enrollment target is 50 participants.
The verdict
NCT05759962, a Phase 1 study, has completed, sponsored by Thryv Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is a single-center, randomized, double-blind, placebo-controlled study to be conducted in 2 parts: single ascending dose (SAD) incorporating a food effect arm and multiple ascending dose (MAD). Potential participants for each part will undergo screening procedures within 28 days of enrollment.
Interventions
- OTHER Placebo
- DRUG LQT-1213
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-09-14 |
| Est. Completion | 2023-03-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05759962
The ClinicalTrials.gov registry entry for NCT05759962 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thryv Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05759962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05759962 about?
NCT05759962 is a clinical study titled "Phase 1 Study of LQT-1213 in Healthy Adults". This is a single-center, randomized, double-blind, placebo-controlled study to be conducted in 2 parts: single ascending dose (SAD) incorporating a food effect arm and multiple ascending dose (MAD). Potential participants for each part will undergo screening procedures within 28 days of enrollment.
What is the current status of trial NCT05759962?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2022-09-14. Estimated completion is 2023-03-05.
What interventions are being tested in trial NCT05759962?
The interventions under investigation include: Placebo (OTHER), LQT-1213 (DRUG).
Who is sponsoring clinical trial NCT05759962?
This trial is sponsored by Thryv Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.